Navigation Links
Medivation Announces Positive New Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients
Date:6/2/2009

-- Findings Presented at American Society of Clinical Oncology 2009 Annual Meeting and Included in Best of ASCO(R) Educational Program --

SAN FRANCISCO, June 2 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced the presentation of new clinical results from a Phase 1-2 trial evaluating MDV3100, a next-generation androgen receptor antagonist, in castration-resistant prostate cancer (CRPC) patients. The new findings, which include data from all 140 enrolled patients, confirm previously reported results that MDV3100 consistently demonstrated anti-tumor activity in both chemotherapy-naive and post-chemotherapy CRPC patients across dose levels and endpoints, as evaluated by reductions in prostate specific antigen (PSA) levels, radiographic findings and circulating tumor cell (CTC) counts.

New findings include the median time to PSA progression, which was 6.1 months for post-chemotherapy patients, with the median time not yet reached for chemotherapy-naive patients. In addition, the median time to radiographic progression was 6.6 months for post-chemotherapy patients, with the median time not yet reached for chemotherapy-naive patients.

"These new clinical data in the post-chemotherapy setting are encouraging because these patients have a poor prognosis, surviving on average a year or less -- with no approved treatment options," said Howard Scher, M.D., principal investigator of the trial and chief of the Genitourinary Oncology Service and the D. Wayne Calloway Chair in Urologic Oncology at Memorial Sloan-Kettering Cancer Center in New York. "These findings suggest that MDV3100, with its unique mechanism of action, provides beneficial clinical effects in contrast to those achieved with first-generation androgen receptor antagonists."

In vitro data recently published in Science'/>"/>

SOURCE Medivation, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pfizer and Medivation Initiate Phase 3 Trial of Dimebon Added to Donepezil in Patients with Alzheimers Disease
2. Medivation Completes Enrollment of Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients
3. Medivation Presents Positive New Data on Dimebons Long-Term Efficacy and Novel Mechanism of Action at the International Conference on Alzheimers Disease
4. Medivation Announces Publication in The Lancet of Dimebon Pivotal Trial Results in Alzheimers Disease
5. Medivation Announces Positive Top-Line Results From Phase 2 Dimebon Study in Huntingtons Disease
6. Medivation to Host Conference Call at 5 p.m. EDT Monday to Discuss Top-Line Phase 2 Study Results in Huntingtons Disease
7. Medivation Initiates Second Pivotal Phase 3 Trial of Dimebon(TM) in Patients With Alzheimers Disease
8. Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients at 44th ASCO Annual Meeting
9. Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting
10. Medivations Dimebon(TM) Significantly Improved Thinking and Memory in Alzheimers Disease Patients Over One Year
11. Medivations Dimebon(TM) Significantly Improved Daily Function in Alzheimers Disease Patients, Resulting in Reduced Need for Caregiver Assistance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Dec. 23, 2014  Medical Science Liaisons play a ... link between the medical device industry and key stakeholders, ... the coming years as the device industry relies on ... to research by benchmarking firm, Best Practices, LLC, one ... important edge is by harnessing new technology to enable ...
(Date:12/22/2014)... 22, 2014 Apnea Sciences ( www.apneasciences.com ) ... Aliso Viejo , California.  Jimmy ... tremendous growth and worldwide expansion, a new facility with ... the anti snore cure have exceeded our expectations and ... are now in 23 countries and will be increasing ...
(Date:12/22/2014)... , Dec. 22, 2014 Research and ... the addition of the "Investment Analysis of ... to their offering. ... in the US medical device sector identifies the ... and venture capital investments, and mergers and acquisitions. ...
Breaking Medicine Technology:Role of Medical Science Liaisons Evolving in Medical Device Sector 2Investment Analysis of the US Medical Device Sector 2
... NARBERTH, Pa., May 22, 2012  Millennium Surgical Corp. / ... to assist nurses and scrub techs who perform ... The resource center provides detailed pictures and ... to protect and sterilize surgical instruments, rigid endoscopes, ...
... May 22, 2012  Unigene Laboratories, Inc. (OTCBB: ... manufacture and development of peptide-based therapeutics today reported ... rats and dogs for its lead proprietary anorexigenic ... anorexigenic peptide selectively targeting the amylin receptor, is ...
Cached Medicine Technology:Millennium Surgical Corp. Develops Online Sterilization Resource Center 2Unigene's Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies 2Unigene's Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies 3Unigene's Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies 4Unigene's Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies 5
(Date:12/25/2014)... TX (PRWEB) December 26, 2014 The ... to 2023” focuses on the current treatment landscape, unmet ... cancer market. TS-1 is an anti-cancer drug which is ... orally and is also used for treating gastric cancer ... and otastat potassium. The drug was first approved in ...
(Date:12/25/2014)... “Every three months the trends for evening ... dress will be one of the hottest styles in the ... Today, the company releases 26 A-line sweetheart evening dresses, and ... , “We are trying our best to help a ... designs. Along with affordable prices, we provide discounted delivery costs ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company ... collection of discounted prom dresses, most of which are ... of the company, the promotion is valid until Jan. ... expand the UK market. , The prom dresses in ... and styles: A-line strapless, empire strapless chiffon, one shoulder, ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 Recently, ... discounts on all its wedding dresses. BellasDress has chosen ... more for gift choices for the holiday season. ... can pick suitable wedding gowns here at discount prices. ... shopping experience at its website. , “All ...
(Date:12/25/2014)... 25, 2014 Helen Harris’ RP (Retinitis ... Hills, California after an 8 year battle with breast ... Eve evening in her home in Woodland Hills California ... cancer. , As the founder and ... she pioneered and championed many of today's greatest breakthroughs ...
Breaking Medicine News(10 mins):Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4
... WEDNESDAY, Dec. 15 (HealthDay News) -- Attending Alcoholics Anonymous ... that jailed women and those recently released from jail ... The new study included 223 women at the Rhode ... considered hazardous drinkers, meaning that when they drank, they ...
... (December 15, 2010) Delaying elective surgical procedures after ... increases the risk of infectious complications and raises hospital ... in the December issue of the Journal of ... of infection following surgical procedures continues to be a ...
... International Bionic Engineering Conference 2011 organised by Elsevier, the ... and services, aims to bridge the gap between academic ... rapidly growing and gaining recognition across many disciplines. ... of ideas, Elsevier is calling upon key researchers in ...
... , WEDNESDAY, Dec. 15 (HealthDay News) -- Genes that ... patients with non-small cell lung cancer have been identified ... lung tumors and nearby healthy lung tissue from 30 ... messenger ribonucleic acid (mRNA) associated with 48 known genes ...
... DALLAS Dec. 14, 2010 Researchers at UT ... in cancer cells and normal tissue that predict survival ... cell lung cancer. "Patient responses to cancer treatment ... among tumors," said Dr. David Mangelsdorf, chairman of pharmacology ...
... TORONTO, Ont. 14, 2010Simple changes to how ventilators are ... for transplants, according to new international research involving a ... deteriorate between the time a patient is declared brain ... determine whether they are suitable for transplant. The study ...
Cached Medicine News:Health News:AA May Help Stem Alcohol Abuse in Female Convicts 2Health News:New research finds delaying surgical procedures increases infection risk and health care costs 2Health News:New international conference in bionic engineering 2Health News:Gene information predicts survival time, possible new treatment options for lung-cancer patients 2Health News:Ventilation changes could double number of lungs available for transplant: study 2
Agglutinating sera for serological identification of E. coli by slide and/or tube agglutination tests. Agglutinating sera are packaged 2 mL / vial....
For presumptive identification of Escherichia coli using enzyme technology. Tests: Indole, MUG...
A direct qualitative enzyme immunoassay for detection of E.coli Shiga Toxin 1 and 2 in fresh or preserved fecal specimens....
Inquire...
Medicine Products: